MarketCap
Facebook
X
Telegram
Rezolute EBITDA | RZLT
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Rezolute
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -82.9 M | -79.9 M | -70.4 M | -56 M | -41.8 M | -22.9 M | -20.5 M | -25.8 M | -25.3 M | -19.2 M | -14.2 M | -10.6 M | -5.16 M | -6.11 M | -45.5 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -45.5 K | -82.9 M | -32.1 M |
Quarterly EBITDA Rezolute
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -17.3 M | -24.2 M | -19.8 M | - | -19.8 M | - | - | - | -16.9 M | - | - | - | -15.9 M | - | - | -14.4 M | -10.2 M | -24.6 M | -10.8 M | -12.1 M | -7.64 M | -19.8 M | -5.48 M | -7.15 M | -3.62 M | -7.15 M | -3.62 M | -6.72 M | -5.17 M | -6.71 M | -5.17 M | -3.15 M | -2.54 M | -3.12 M | -2.3 M | -5.48 M | -6.45 M | -5.22 M | -6.45 M | -4.61 M | -3.56 M | -4.61 M | -3.56 M | -3.92 M | -3.23 M | -3.92 M | -3.23 M | -3.04 M | -2.21 M | -3.01 M | -2.21 M | -649 K | -700 K | -648 K | -700 K | -500 K | -543 K | - | -94.6 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -94.6 K | -24.6 M | -7.02 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
32.3 M | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Allakos
ALLK
|
-115 M | - | - | $ 28.6 M | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-241 M | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
12.8 M | $ 1.89 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
-44.2 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-76 M | - | - | $ 401 M | USA |
 |
Evelo Biosciences
EVLO
|
-106 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-10.3 M | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
489 M | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
-51.1 M | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
BioNTech SE
BNTX
|
-1.4 B | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-96.7 M | - | - | $ 384 M | Britain |
 |
Genocea Biosciences
GNCA
|
-50.5 M | - | -15.0 % | $ 3.04 M | USA |
 |
Burford Capital Limited
BUR
|
232 M | $ 3.63 | 3.93 % | $ 795 M | Britain |
|
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M | Britain |
 |
G1 Therapeutics
GTHX
|
-39 M | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
Catalyst Biosciences
CBIO
|
14 M | $ 14.24 | 0.35 % | $ 1.27 B | USA |
 |
C4 Therapeutics
CCCC
|
-113 M | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
-36.5 M | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
-7.26 M | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
15.8 B | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
-68.3 M | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
-180 M | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
-199 M | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
-86.9 M | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
-284 M | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-10.6 M | $ 4.12 | 1.98 % | $ 50.3 M | Israel |
 |
Фармсинтез
LIFE
|
-22.6 M | - | - | - |  Russia |
 |
Cellectar Biosciences
CLRB
|
-22.8 M | $ 2.08 | 0.48 % | $ 5.43 M | USA |
 |
IGM Biosciences
IGMS
|
-199 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
-10.9 M | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
-120 M | - | - | $ 123 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Karuna Therapeutics
KRTX
|
-493 M | - | - | $ 12.2 B | USA |
 |
Cocrystal Pharma
COCP
|
-8.95 M | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-513 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
64.9 M | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
45.9 M | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
-96.5 M | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-85.1 M | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
Curis
CRIS
|
-5.54 M | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
151 M | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-645 M | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
-42.9 M | $ 11.8 | 8.21 % | $ 932 M | USA |
|
Champions Oncology
CSBR
|
260 K | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-37.8 M | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
-25.6 M | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
-22.8 M | $ 1.72 | 2.38 % | $ 13.8 M | USA |